EAM
AXSM icon

Eventide Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Eventide Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.8M Sell
519,558
-51,668
-9% -$8.92M 1.45% 14
2025
Q4 		$104M Sell
571,226
-175,172
-23% -$24.5M 1.63% 10
2025
Q3 		$90.6M Buy
746,398
+20,726
+3% +$2.33M 1.49% 14
2025
Q2 		$75.7M Sell
725,672
-19,178
-3% -$2.03M 1.33% 17
2025
Q1 		$86.9M Sell
744,850
-83,861
-10% -$9.55M 1.73% 9
2024
Q4 		$70.1M Buy
828,711
+824
+0.1% +$75.8K 1.28% 23
2024
Q3 		$74.4M Sell
827,887
-110,827
-12% -$9.67M 1.28% 22
2024
Q2 		$75.6M Buy
938,714
+592,002
+171% +$43.8M 1.29% 23
2024
Q1 		$27.7M Hold
346,712
– – 0.43% 71
2023
Q4 		$27.6M Hold
346,712
– – 0.45% 67
2023
Q3 		$24.2M Buy
+346,712
New +$25.9M 0.44% 68

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eventide Asset Management's AXSM Position: Q1 2026 in Review

Eventide Asset Management reduced its Axsome Therapeutics (AXSM) stake by 9% in Q1 2026, selling an estimated $8.92M and leaving 519,558 shares worth $87.8M. The position accounts for 1.45% of the portfolio, ranked #14.

Eventide Asset Management first reported a position in AXSM in Q3 2023 and has held it in 11 quarters since. The position peaked at $104M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Eventide Asset Management held 519,558 shares of Axsome Therapeutics worth $87.8M as of Q1 2026.
  • Eventide Asset Management sold 51,668 Axsome Therapeutics shares in Q1 2026, an estimated $8.92M.
  • Axsome Therapeutics made up 1.45% of Eventide Asset Management's portfolio in Q1 2026, its #14 holding.
  • Eventide Asset Management first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Eventide Asset Management's Axsome Therapeutics position peaked at $104M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.